• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Ether and amide derivatives are disclosed, which are represented by the following formula (I) and its pharmaceutical acceptable salt, and which are useful for the treatment of diabetes. (with the provisos that (i) when A is —O—, then n is 2 or 3 (ii) when A is then n is 1 or 2. R3 is OH—, CH3SO2NH—, CF3SO2NH—, CH3SO2NHCH2—, CF3SO2NHCH2—, HOOC—, CH3OOC—, HOOC—CH2SO2NH—, CF3—CH2SO2NH—, R8—NHSO2—, R8—NHSO2—CH2—, HOOC—CH2—O—, HSO3N═CH—, or R9—SO2NHCO—; R4 is H, OH, O-alkyl or O—CH2OCH3; R5 is H, halogen atom, —CH2COOH or OH; R6 and R7 are hydrogen, t-butyl or pyrolidyl; R8 is hydrogen or lower alkyl; R9 is alkyl or thienyl; R10 is lower alkyl) or a pharmaceutically acceptable salt.
    公开号:US20010008898A1
    申请号:US09/756,701
    申请日:2001-01-10
    公开日:2001-07-19
    发明作者:Tsuyoshi Tomiyama；Akira Tomiyama；Hiroshi Tomiyama；Keiko Kuroiwa
    申请人:Kotobuki Seiyaku Co Ltd；
    IPC主号:C07D213-30
    专利说明:
    [0001] Field of the Invention [0001]
    [0002] This invention is regarding to new ether and/or amide derivatives which are useful for the treatment of diabetes and a pharmaceutical composition containing these compounds as active ingredients. [0002]
    [0003] Current Technology [0003]
    [0004] Biguanide and sulfonyl urea derivatives have been used as anti-diabetics so far. But these compounds have some drawbacks. For instance, biguanide compounds cause diabetic acidosis and sulfonyl urea compounds often cause hypoglycemia and it is required to be careful for taking these drugs. [0004]
    [0005] Recently, thiazolidine-2,4-dion derivatives are reported to have blood glucose lowering activities. [0005]
    [0006] For example, Troglitazone (T. Yoshioka et al., J.Med.Chem. 1989,32,421), Pioglitazone (H. Ikeda et al., J.Med.Chem. 1992,35,2617) or Rosiglitazone (B. C. C. Cantello et al., J.Med.Chem. 1994,37, 3977) are mentioned as Thiazolidine-2,4-dione derivatives and Troglitazone is applied for clinical use. [0006]
    [0007] However, these thiazolidime-2,4-dione compound are reported to cause of liver toxicity (R. Perfetti et al., Diabetes/Metabolism Review 1998,14(3),207) and further, side effect to troglitazone treatment have been reported. They include cardiomegaly and hepatic malfunction such as increasements of amino transferase (AST), alanin transferees (ALT), and lactic dehydrogenase (LDH). (R. R. Henry, Endocrinol.Metab,Clin,North Am. 1997,26,553). [0007]
    [0008] To alleviate the side effect of thiazolidine-2,4-dione derivatives, several non-thiazolidine-2,4-diones are reported such as oxazoline-2,4-diones are reported such as oxazoline-2,4-dione (R. L. Dow et al., J.Med.Chem. 1991,34,1538), 1-oxo-2,4-diazoline-3,5-dione (S. W. Goldstein et al., J.Med.Chem. 1993,36,2238), α-amino carboxylic acid (R. A. DeFronzo, Diabetes, 1988,37,667), and Dicarboxylic acid ester (H. Shinkai et al., J.Med.Chem.1998,41,1927). [0008]
    [0009] The Subject of Invention [0009]
    [0010] The present invention concerns ether and amide compounds which enhance insulin action and show hypoglycemic activity with low toxicities and a pharmaceutical composition containing these compounds as active ingredients. [0010]
    [0011] A Solution to the Problem [0011]
    [0012] After elaborated to make an anti-diabetic drug, the inventors found that new compounds as show general formula (I) had shown potent anti-diabetic activities and fulfilled this invention. [0012]
    [0013] Namely, the invention is the compounds as shown in general formula (I) and its pharmaceutically acceptable salts and a composition containing these compounds as active ingredients.[0013]
    [0014] [0014]
    [0015] (with the provisos that (i) when A is —O—, then n is 2 or 3 (ii) when A is [0015]
    [0016] then n is 1 or 2. R[0016] 3 is OH—, CH3SO2NH—, CF3SO2NH—, CH3SO2NHCH2—, CF3SO2NHCH2—, HOOC—, CH3OOC—,
    [0017] HOOC—CH[0017] 2SO2NH—, CF3—CH2SO2NH—,
    [0018] R[0018] 8—NHSO2—, R8—NHSO2—CH2—, HOOC—CH2—O—, HSO3N═CH—, or R9—SO2NHCO—;
    [0019] R[0019] 4 is H, OH, O-alkyl or O—CH2OCH3;
    [0020] R[0020] 5 is H, halogen atom, —CH2COOH or OH;
    [0021] R[0021] 6 and R7 are hydrogen, t-butyl or pyrolidyl;
    [0022] R[0022] 8 is hydrogen or lower alkyl;
    [0023] R[0023] 9 is alkyl or thienyl;
    [0024] R[0024] 10 is lower alkyl).
    [0025] Enforcement of Invention [0025]
    [0026] 70 compounds are exemplified as follow, but the invention is not limited to these compounds. Further the preparation of the compounds 1-70 are exemplified in each experimental sections. [0026]
    [0027] Typical preparations of the compounds of general formula (I) according to the invention are shown. [0027]
    [0028] (I) The preparation of a compound of general formula (I) in which [0028]
    [0029] A is —O—; R[0029] 2 is
    [0030] (wherein: R[0030] 5, R6, and R7 have the above-mentioned meanings; n=2)
    [0031] (a) In case of [0031]
    [0032] R[0032] 1 is
    [0033] in which R[0033] 3 is CH3SO2NH— or CF3SO2NH— and R4 is H.
    [0034] The compounds can be obtained by means of the following reaction diagram: Asparatic acid β-methyl ester (2). (J.Arg.Chem.Soc.Japan, 1951-1952,25,129):C.A.47,6065i or R. L. Prestige et al., J.Org.Chem. 1975,40,3287 as a starting material is converted to compound (3) by the known method (B. Helvin et al., J.Med.Chem. 1992,35,1853) and compound (3) is tosylated or mesylated to obtain compound (4). The coupling reaction of compound (4) with nitrophenol to obtain compound (5) and then compound (5) is reduced with H[0034] 2—Pd/C to obtain compound (6) and compound (6) is subjected to react with several sulfonyl chloride (7) and sulfonic acid anhydride (8) to obtain the compound of genaral formula (I).
    [0035] (b) In case of [0035]
    [0036] R[0036] 1 is
    [0037] in which R[0037] 3 is HOOCCH2SO2NH— and R4 is H.
    [0038] The compounds can be obtained by mean of the following reaction diagram: [0038]
    [0039] The reaction of compound (6) and EtOOC.CH[0039] 2SO2Cl as a sulfonyl chloride, namely CH3OOCCH2SO2Cl (9), to obtain the ester (11) and then compound (11) is hydrolyzed to obtain the compound of genaral formula (I).
    [0040] The above mentioned compound (9) is obtained by the chlorination of sulfoacetic acid (HOOCCH[0040] 2SO3H(10)) with SOCl2 and then reacted with alcohol (R. L. Hinman et al. (J.Am.Chem. Soc. 1959,81,5655), (H. T. Lee et al., Bioorg.Med.Chem.Lett. 1998,8,289).
    [0041] (c) In case of [0041]
    [0042] R[0042] 1 is
    [0043] in which R[0043] 3 is HOOC—CONH— and R4 is H.
    [0044] The compound can be obtained by means of the following reaction diagram: [0044]
    [0045] The reaction of compound (6) and methyloxalate to obtain compound (12) and compound (12) is hydrolyzed to obtain the compound of general formula (I). Further compound (12) is N-alkylated with alkylhalide and ther subjected to hydrolyze to obtain the compound of general formula (I). [0045]
    [0046] in which R[0046] 3 is CH3SO2NHCH2—, CF3SO2 NHCH2— and HOOC—CONH—, and R4 is H.
    [0047] The compound can be obtained by means of the following reaction diagram: [0047]
    [0048] Compound (4) is reacted with p-hydroxy benzaldehyde to obtain compound (13) and compound (13) is subjected to reductive amination using benzylamine and sodium borohydride to obtain compound (14). [0048]
    [0049] After debenzylation of compound (14) in H[0049] 2—Pd/C, compound (15) is obtained. Compound (15) is reacted with sulfonyl chloride, sulfonic acid anhydride, EtOOC.CH2SO2Cl or methyloxalate as the same manner as in case of compound (6) and compound (12), then the compound of general formula (I) is obtained.
    [0050] (e) In case of [0050]
    [0051] R[0051] 1 is
    [0052] in which R[0052] 3 is HOOC— or CH3OOC— and R4 is —OH or —O-alkyl.
    [0053] As shown in the following reaction diagram, [0053]
    [0054] compound (32) and compound (3) is subjected to the MITSUNOBU reaction to obtain the compound (33) which is the compound of general formula (I). [0054]
    [0055] Further, compound (33) can be converted to compound (34) and compound (36) as shown in the following diagram. [0055]
    [0056] (f) In case of [0056]
    [0057] R[0057] 1 is
    [0058] in which R[0058] 3 is NH2SO3— or alkyl-NHSO2— and R4 is —OH.
    [0059] As shown in the following reaction diagram, [0059]
    [0060] according to the literature method (J.Med.Chem. 1997,20,1235), compound (51) and (52) are obtained from resorcin dimethyl ether (50). [0060]
    [0061] Further, obtained compounds (51) and (52) are reacted with compound (4) to obtain general formula (I) as follow. [0061]
    [0062] (g) In case of [0062]
    [0063] R[0063] 1 is
    [0064] in which R[0064] 3 is CH3SO2NH— or CF3SO2NH—.
    [0065] As shown in the following reaction diagram, [0065]
    [0066] compound (53) is subjected to the MITSUNOBU reaction to obtain compound (54) and reduction of compound (54) yields compound (55). Compound (55) is converted to compound (56) according to the method of the preparation of compound (42) from compound (39). [0066]
    [0067] (h) In case of [0067]
    [0068] R[0068] 1 is
    [0069] in which R[0069] 3 is —COOH.
    [0070] As shown in the following reaction diagram, [0070]
    [0071] compound (57) is reacted with compound (4) and obtain the ether compound (58) and the resulting compound (58) is hydrolyzed to obtain compound (59) which is the compound of general formula (I). [0071]
    [0072] (i) In case of [0072]
    [0073] R[0073] 1 is
    [0074] in which R[0074] 3 is MeOOCCH2—, and R4 is —O-alkyl.
    [0075] As shown in the following reaction diagram, [0075]
    [0076] compound (61), which is obtained from compound (60), is reacted with compound (4) to obtain the compound of general formula (I). [0076]
    [0077] (j) In case of [0077]
    [0078] R[0078] 1 is
    [0079] in which R[0079] 3 is NH2SO2CH2— or alkyl-NHSO2CH2— and R4 is OH or —O-alkyl.
    [0080] As shown in the following reaction diagram, [0080]
    [0081] after reduction of compound (62), the obtained compound (63) is reacted with Na[0081] 2SO3 to obtain compound (64) according to the reported method (J.C.S.Chem.Comom., 1989,521). Then compound (64) is chlorinated with POCl3 and treated with aqueous NH3 to obtain the amide compound (65). After debenzylation of compound (65), compound (66) is obtained. Compound (66) is reacted with compound (4) to yield the compound of general formula (I).
    [0082] (II) The preparation of a compound of general formula (I) in which [0082]
    [0083] A is —O—; R[0083] 2 is
    [0084] (wherein: R[0084] 5, R6, and R7 have the above mentioned meaning; n=3)
    [0085] (a) In case of [0085]
    [0086] R[0086] 1 is
    [0087] in which R[0087] 3 is CH3SO2NH— or CF3SO2NH—, and R4 is H.
    [0088] As shown in the following reaction diagram, [0088]
    [0089] glutamic acid γ-methyl ester (16) is used in stead of aspartic acid β-methyl ester (2). Compound (17) is obtained from compound (16) by the same method as compound (3) is obtained from compound (2). [0089]
    [0090] After compound (17) is halogenated, tosylated or mesylated, obtained compound (18) is coupled with nitrophenol and the resulting compound (19) is hydrogenated to obtain compound (20). The obtained compound (20) is reacted with several sulfonyl chlorides, sulfonic acid anhydrides, EtOOC.H[0090] 2SO2Cl or methyloxalate to obtain the compound of general formula (I).
    [0091] (III) The preparation of a compound of general formula (I) in which [0091]
    [0092] A is —O—; R[0092] 2is
    [0093] (a) In case of [0093]
    [0094] R[0094] 1 is
    [0095] in which R[0095] 3 is CH3SO2NH— or CF3SO2NH—, and R4 is H.
    [0096] As shown in the following reaction diagram, [0096]
    [0097] after the reaction of 2-methyl 5-ethylpyridine (21) and formaldehyde using the reported method (Japanese Patent Publication, 1981-65870), compound (22) is obtained. After compound (22) is halogenated, tosylated or mesylated, obtained compound (23) is coupled with nitrophenol and the resulting compound (24) is hydrogenated to obtain compound (25), by the same method as compound (4) is obtained from compound (3). [0097]
    [0098] The obtained compound (25) is reacted with several sulfonylchlorides (7), sulfonic acid anhydrides (8), EtOOC.CH[0098] 2SO2Cl or methyloxalate to obtain the compound of general formula (I).
    [0099] (b) In case of [0099]
    [0100] R[0100] 1 is
    [0101] in which R[0101] 3 is CH3SO2NH— or CF3SO2NH—, and R4 is —OH or —O-alkyl.
    [0102] As shown in the following reaction diagram, [0102]
    [0103] compound (37) is reacted with HO—R[0103] 2 to obtain compound (38) and compound (38) is hydrogenated to compound (39), or compound (38) is alkylated to compound (40) and reduction of compound (40) is resulting compound (41) . Then compound (39) or (41) are reacted with RSO2Cl and obtain compound (42) or compound (43).
    [0104] Compound (37) in the diagram can be obtained from resorcin as follow. [0104]
    [0105] And compound (42) and (43) can be obtained by using the reported method of coupling reaction of fluorobenzene and alcholol (Bioorg.Med.Chem.Lett., 1994,4 (10),1181). Namely, 2—OMOM (methoxy methyl)-4-fluoro nitrozenzene (45) is reacted with HO—R[0105] 2 to give compound (46) and resulting compound (46) is reduced to obtain compound (47).
    [0106] Compound (47) is reacted with RSO[0106] 2Cl to obtain compound (48) and after deprotection of MOM-group in compound (48), compound (42) is obtained.
    [0107] Instead of compound (45), compound (49) is also converted to compound (41), and compound (43) is obtained from compound (41) by the same method as compound (48) is obtained from compound (46). [0107]
    [0108] The process is shown in the following reaction diagram. [0108]
    [0109] (IV) The preparation of a compound of general formula (I) in which [0109]
    [0110] A is —O—; R[0110] 2 is
    [0111] (a) In case of [0111]
    [0112] R[0112] 1 is
    [0113] in which R[0113] 3 is CH3SO2NH— or CF3SO2NH—, and R4 is —H.
    [0114] As shown in the following reaction diagram, [0114]
    [0115] compound (28), obtained from 2-chloropyridine (26) or 2-methyl amino pyridine (27), is tosylated or mesylated to obtain compound (29). Compound (29) is subjected to coupling reaction with nitro phenol and obtained compound (30) using the same manner to obtain compound (3). Resulting compound (30) is reduced to obtain compound (31) and compound (31) is reacted several sulfonyl chlorides (7), sulfonic acid anhydrides (8), EtOOC.CH[0115] 2SO2Cl and methyloxalate to obtain the compound of general formula (I).
    [0116] (V) The preparation of a compound of general formula (I) in which [0116]
    [0117] A is —NH—CO— [0117]
    [0118] (a) In case of [0118]
    [0119] R[0119] 1 is
    [0120] in which R[0120] 3 is CH3SO2NH— or CF3SO2NH—, and R4 is —H.
    [0121] As shown in the following reaction diagram, [0121]
    [0122] compound (67), intermediate for compound (3), is obtained according to the reported method (J.Med.Chem. 1999,35,1853) and compound (67) is hydrolyzed to obtain compound (68). After chlorination of compound (68), obtained chloride is reacted with p-nitroaniline to obtain compound (69). [0122]
    [0123] Then compound (69) is hydrogenated to obtain compound (70) according to the same method to prepare compound (5). Compound (70) is reacted several sulfonyl chlorides (7), sulfonic acid anhydrides (8), EtOOC.CH[0123] 2SO2Cl or methyloxalate to obtain the compound of general formula (I).
    [0124] (b) In case of [0124]
    [0125] R[0125] 1 is
    [0126] in which R[0126] 3 is R9SO2NHCO— (R9=alkyl or thienyl), and R4 is H.
    [0127] As shown in the following reaction diagram, [0127]
    [0128] carboxylic acid of compound (71) is reacted with CDI (Carbonyl Diimidazole) and then subjected to react with sulfamine of compound (72) in the presence of DBU (1,8-Diazabicyclo[5,4,0]undeca-7-ene) and obtain the compound of general formula (I). (Bioorg.Med.Chem. Lett. 1995,1155) [0128]
    [0129] As pharmaceutical acceptable salts of a compound of general formula (I), sodium salt, potassium salt and inorganic base are mentioned. [0129]
    [0130] In case of R[0130] 1 contains pyridine base, salts of inorganic and organic acids are mentioned. As the salt of inorganic acid, hydrochloride and sulfate are mentioned. As the salt of organic acid, acetate, succinate and fumalate are mentioned.
    [0131] A compound of general formula (I) can be used itself or formulated to pharmaceutical product such as powder, granule, tablet and capsule by known pharmaceutical technology. [0131] Pharmacological Experiment
    [0132] Hypoglycemic activity in mice [0132]
    [0133] Test compounds were suspended in 0.5% Methyl cellulose solution and administered (p.o.) to db/db mice (obtained from Nihon Clea) at a range of 3-30 mg/kg once a day for four consecutive days. Troglitazone (300 mg/kg) was also administered for control. The results is shown in Table 1. [0133]
    [0134] The compound number corresponds to the experimental number. [0134] TABLE 1 Compound No. Dosage (mg/kg) Hypoglycemic activity (%)1 30 24.6 2 10 49.0 8 10 26.0 9 10 24.0 10 10 32.4 11 10 15.4 18 10 34.7 19 10 12.8 21 10 34.6 24 10 25.7 26 30 15.1 30 30 22.1 31 30 19.0 35 30 28.8 40 30 53.4 42 10 29.6 47 10 25.6 48 30 65.4 50 30 21.9 52 30 10.5 57 3 44.0 58 3 43.4 59 3 18.4 63 3 18.4 67 3 33.1 68 3 21.2 70 30 51.0 Troglitazone 300 34.0 EXAMPLE
    [0135] The following Examples are provided only for the purpose of the preparation of the compound and not restrict the disclosed invention. [0135] Example 1
    [0136] 4-[2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy]benzene methylsulfonamide [0136]
    [0137] (a) 5-Methyl-4-tosyloxyethyl-2-phenyl-oxazole [0137]
    [0138] 22.2 g of 5-Methyl-4-hydroxyethyl-2-phenyl-oxazole was dissolved in a mixture of pyridine (13 mL) and dichloroethane (6 mL) and toluenesulfonyl chloride was added slowly to the mixture and stirred at room temperature over night. The reaction mixture was poured into water and extracted with ethyl acetate (50 mL) . The organic extract was washed with satd. CuSO[0138] 4 solution, H2O and satd. NaCl solution. Removal of solvents after drying over anhydro. Na2SO4, followed by column chromatography (ethyl acetate:n-hexane=1:1) yielded 3.33 g (87.6%) of a white solid of the objective compound.
    [0139] MASS(m/e):371(M+),216,186(BP),156,130,105,77,51 [0139]
    [0140] IR(cm[0140] −1):1359,1173,966,927,834,813,753,666
    [0141] [0141] 1HNMR(CDCl3) δ: 2.01-2.08 (m, 2H, —CH2—), 2.29 (S, 3H, —CH3), 2.42 (S, 3H, —CH3), 2.55 (t, 2H, —CH2—, J=6.83,7.33 Hz), 4.08 (t, 2H, —CH2—, J=5.86,6.34 Hz), 7.31 (d, 2H, aromatic, J=7.81 Hz), 7.40-7.43 (m, 3H, aromatic), 7.78 (d, 2H, aromatic, J=8.3 Hz), 7.93 (dd, 2H, aromatic, J=7.33, 7.81 Hz)
    [0142] (b) 5-Methyl-4-p-nitrophenoxyethyl-2-phenyl-1,3-oxazole [0142]
    [0143] 0.21 g of NaH was placed in a 50 mL flask and washed twice with n-hexane and added 10 mL of dimethylformamide. 0.67 g of p-nitrophenol was added to the solution at 0° C. and stirred for 30 min. To this mixture, the compound (1.8 g) obtained from the above mentioned step (a) in dimethyl formamide (5 mL) was added and stirred at 80° C. over night. After cooling, the reaction mixture was poured into water and the product was extracted with ethyl acetate (80 mL). The ethyl acetate phase was washed with H[0143] 2O, satd. NaCl solution and dried over Na2SO4 and filtered. Evaporation of the filtrate gave a residue, from which 1.24 g (75.6%) of the yellowish objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane=1:3). m.p.=100-103° C.
    [0144] MASS(m/e):338(M+),200,173(BP),130,104,77,51 [0144]
    [0145] IR(cm[0145] −1):1590,1500,1332,1263,1107,840
    [0146] [0146] 1HNMR(CDCl3) δ: 2.18-2.24 (m, 2H, —CH2—), 2.29 (S, 3H, —CH3), 2.71 (t, 2H, —CH2—, J=7.33, 6.83 Hz), 4.09 (t, 2H, —CH2—, J=6.35, 5.86 Hz), 6.95 (d, 2H, aromatic, J=9.28 Hz), 7.41-7.44 (m, 3H, aromatic), 7.97 (dd, 2H, aromatic, J=7.32, 7.82 Hz), 8.19 (d, 2H, aromatic, J=9.28 Hz)
    [0147] (c) 5-Methyl-4-p-aminophenoxyethyl-2-phenyl-1,3-oxazole [0147]
    [0148] 1.23 g of the compound obtained from the above mentioned step (b) was dissolved in a solution of 25 mL of methanol-tetrahydrofuran (1:1) and added 0.25 g of 5% Pd—C. To this solution was introduced hydrogen-gas for 1 hour. After filtration of the reaction mixture, the filtrate was evaporated to give a residue, from which 1.02 g (91.1%) of the objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane=1:1). m.p.=57-59° C. [0148]
    [0149] MASS(m/e):308(M+),200(BP),174,104,80,53 [0149]
    [0150] IR(cm[0150] −1):1512,1242,825,711,681
    [0151] [0151] 1HNMR(CDCl3) δ: 2.08-2.15 (m, 2H, —CH2—), 2.28 (S, 3H, —CH3), 2.68 (t, 2H, —CH2—, J=7.33, 7.32 Hz), 3.42 (bs, 2H, —NH2), 3.90 (t, 2H, —CH2—, J=6.35, 5.86 Hz), 6.62-6.66 (m, 2H, aromatic), 6.73-6.76 (m, 2H, aromatic), 7.38-7.45 (m, 2H, aromatic), 7.96-7.99 (m, 2H, aromatic)
    [0152] (d) 4-[2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzene methylsulfonamide (compound 1) [0152]
    [0153] To a mixture of 0.4 g of the compound obtained from the above mentioned step (c) and 0.28 mL of triethylamine in dichloroethane (4 mL) and 0.16 mL of mesyl chloride were added and stirred at 30° C. for 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate phase was washed with satd. NH[0153] 4Cl solution, water and satd. NaCl solution and dried over anhydrous Na2SO4 and filtrated. Evaporation of the filtrate gave a residue, from which 0.34 g (66.7%) of the off-white objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane =1:1). m.p.=121-123° C.
    [0154] MASS(m/e):372(M+),264,186(BP),149,104,79,55 [0154]
    [0155] IR(cm[0155] −1):3238,1506,1320,1281,1245,1212,1143,777
    [0156] [0156] 1HNMR(CDCl3) δ: 2.38 (S, 3H, —CH3), 2.93 (S, 3H, —SO2CH3), 2.98 (t, 2H, —CH2—, J=6.35, 6.84 Hz), 4.23 (t, 2H, —CH2—, J=6.83, 6.84 Hz), 6.25 (S, 1H, —NH), 6.88 (d, 2H, aromatic, J=8.79 Hz), 7.16 (d, 2H, aromatic, J=9.27 Hz), 7.39-7.45 (m, 3H, aromatic), 7.97 (dd, 2H, aromatic, J=1.46, 1.95 Hz) Example 2
    [0157] 4-[2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzene trifluoromethyl sulfonamide (compound 2) [0157]
    [0158] To a mixture of the compound (0.4 g) obtained from Example 1 step (c) in 4 mL of dichloromethane and 0.27 mL of triethylamine was added trifluoromethanesulfonic acid anhydride (3.3 mL) and stirred for 30 minutes at 0° C. To the reaction mixture were added 2 mL of methanol and 1 mL of 10% NaOH solution and the mixture was stirred for 10 minutes, followed by addition of water (20 mL) and extracted with ethyl acetate. The extract was washed with satd. NH[0158] 4Cl, water and satd. NaCl and dried over anhydrous Na2SO4. After filtrating, the extract was evaporated and the residue was purified by silicagel column chromatography. Using a eluants (ethyl acetate:n-hexane=1:1), 0.38 g (66.7%) of the objective compound was obtained. m.p.=97-99° C.
    [0159] MASS(m/e):441 (M+),200(BP),173,104,69 [0159]
    [0160] IR(cm[0160] −1): 1455,1248,1215,1116,894,597
    [0161] [0161] 1HNMR(CDCl3) δ: 2.17-2.23 (m, 2H, —CH2—), 2.29 (S, 3H, —CH3), 2.70 (t, 2H, —CH2—, J=6.83, 7.33 Hz), 4.05 (t, 2H, —CH2—, J=5.86, 6.34 Hz), 6.97 (d, 2H, aromatic, J=8.79 Hz), 7.40-7.44 (m, 3H, aromatic), 7.98 (dd, 2H, aromatic, J=7.32, 8.30 Hz) Example 3
    [0162] 5-Methyl-4-[2-(4-carboxymethylsulfonylamino)phenoxy]ethyl-2-phenyl-1,3-oxazole (compound 3) [0162]
    [0163] (a) 5-Methyl-4-[2-(4-ethoxycarbonylmethyl sulfonylamino)phenoxy]ethyl-2-phenyl-oxazole [0163]
    [0164] To a solution of the compound (0.36 g) obtained from the above mentioned Example 1 step (c) and triethylamine (0.26 mL) in dichloroethane (8 mL) was slowly added ethoxy carbonyl chloride (0.27 g) at 0° C. and stirred for 2 hours. The reaction mixture was poured into water and the product was extracted with ethyl acetate. The extract was washed with satd. NH[0164] 4Cl, water and satd. NaCl and dried over anhydrous Na2SO4 and filtrated. Evaporation of the filtrate gave a residue, from which 0.32 g (59.1%) of the oily objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane =1:1).
    [0165] MASS(m/e):443(M+),186(BP),144,108,84,47 [0165]
    [0166] IR(cm[0166] −1): 1734,1341,1299,1248,1158,753
    [0167] [0167] 1HNMR(CDCl3) δ: 1.32 (t, 3H, —COOEt, J=6.84, 7.32 Hz), 2.38 (S, 3H, —CH3), 2.98 (t, 2H, —CH2—, J=6.83, 6.35 Hz), 3.86 (S, 2H, —CH2—), 4.23 (t, 2H, —CH2—, J=6.83, 6.35 Hz), 4.28 (q, 2H, —COOEt, J=7.32, 6.83 Hz), 6.74 (S, 1H, —SO2NH), 6.88 (d, 2H, aromatic, J=8.78 Hz), 7.25 (d, 2H, aromatic, J=8.30 Hz), 7.39-7.44 (m, 3H, aromatic), 7.97 (q, 2H, aromatic, J=1.46, 1.96 Hz)
    [0168] (b) 5-Methyl-4-[2-(4-carboxymethyl sulfonylamino)phenoxy]ethyl-2-phenyl-1,3-oxazole (compound 3) [0168]
    [0169] To a solution of the compound (0.3 g) obtained from the above mentioned step (a) in ethanol (5 mL) was added 10% NaOH (2.5 mL) and the solution was stirred for 1 hour. After removing the solvent, the residue was dissolved in water and washed with ether. After acidification with 10% HCl, the water phase was extracted with ethyl acetate. The ethyl acetate phase was washed with water, satd. NaCl and dried over anhydrous Na[0169] 2SO4. After removing the solvent, the residue was recruptallized from ethyl acetate. 0.2 g (71.4%) of the objective compound was obtained. m.p.=164-167° C.
    [0170] MASS(m/e):371(M+—COOH),294,186(BP),144,104,77 [0170]
    [0171] IR(cm[0171] −1):3274,1713,1512,1338,1281,1245,1158,1107
    [0172] [0172] 1HNMR (CDCl3) δ:2.42 (S, 3H, —CH3), 3.06 (t, 2H, —CH2—, J=6.35 Hz), 3.86 (S, 2H, —CH2—), 4.24 (t, 2H, —CH2—, J=6.83, 6.35 Hz), 6.85 (d, 2H, aromatic, J=9.28 Hz), 7.22 (d, 2H, aromatic, J=8.78 Hz), 7.45-7.47 (m, 3H, aromatic), 7.95 (q, 2H, aromatic, J=2.44, 3.9 Hz) Example 4-5
    [0173] According to the method described in Example 3, compound 4 (oil), compound 5 (m.p.=273-239° C.), compound 6 (m.p.=143-145° C.) and compound 7 (m.p.=114-116° C.) were obtained. [0173] Example 8
    [0174] 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy)phenyl]amino-2-oxo-acetic acid (compound 8) [0174]
    [0175] (a) 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy)phenyl]amino-2-oxo-acetic acid methyl aster [0175]
    [0176] A mixture of the compound (0.5 g) obtained from the above mentioned Example 1 step (c) and methyl oxalate (0.6 g) in methanol (10 mL) was refluxed over night. After cooling, the solvent was evaporated and a resulting residue was purified by silicagel column chromatography. Chloroform was used as a eluant. 0.55 g (84.6%) of the objective compound was obtained. m.p.=128-132 [0176]
    [0177] MASS(m/e):380(M+),321,186(BP),144,105,59 [0177]
    [0178] [0178] 1HNMR(CDCl3) δ: 2.37 (S, 3H, —CH3), 2.98 (t, 2H, —CH2—, J=6.84, 6.35 Hz), 3.96 (S, 3H, —COOMe), 4.24 (t, 2H, —CH2—, J=6.35, 6.83 Hz), 6.90 (d, 2H, aromatic, J=8.79 Hz), 7.38-7.44 (m, 3H, aromatic), 7.53 (d, 2H, aromatic, J=8.79 Hz), 7.97 (d, 2H, aromatic, J=5.86 Hz), 8.76 (d, S, 1H, —NH)
    [0179] (b) 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy)phenyl]amino-2-oxo-acetic acid (compound 8) [0179]
    [0180] A mixture of the compound (0.53 g) obtained from the above mentioned Example 8 step (a) and 10% NaOH in methanol (15 mL) was stirred for 1 hour and water (30 mL) was added to the mixture, followed by acidification (pH 4) with 10% HCl to give a crptalline product. Recrystallization from ethyl acetate gave the objective compound (0.42 g, 82.3%). m.p.=196-198° C. [0180]
    [0181] MASS(m/e):366(M+),322,294,186(BP),144,104,77 [0181]
    [0182] [0182] 1HNMR(CDCl3) δ: 2.36 (S, 3H, —CH3), 2.92 (t, 2H, —CH2—, J=6.35, 6.83 Hz), 3.32 (bs, 1H, —NH), 4.19 (t, 2H, —CH2—, J=6.34, 6.84 Hz), 6.93 (d, 2H, aromatic, J=9.27 Hz), 7.45-7.55 (m, 3H, aromatic), 7.67 (dd, 2H, aromatic, J=2.44 Hz), 7.91 (dd, 2H, aromatic, J=1.47, 1.95 Hz) Example 9
    [0183] 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy)benzyl]trifluoromethylsulfonamide (compound 9) [0183]
    [0184] (a) 5-Methyl-4-(2-p-benzylaminophenoxy)-ethyl-2-phenyl-1,3-oxazole [0184]
    [0185] A mixture of 5-methyl-4-[2-(p-formylphenoxy)]ethyl-2-phenyl-1,3-oxazole (0.54 g) and benzylamine (0.21 mL) in methanol (10 mL) was stirred for 10 minutes and NaBH[0185] 3CN (0.11 g) was added to the mixture. The mixture was stirred over night and evaporated and to a resulting residue was added 10% HCl with stirring, followed by addition of satd. NaHCO3 to alkalize. The product was extracted with ethyl acetate. The ethyl acetate phase was washed with H2O, satd. NaCl and dried over anhydrous Na2SO4 and filtered. Evaporation of the filtrate gave a residue, from which 0.43 (61.4%) of the oily objective product was obtained by silicagel column chromatography.
    [0186] MASS(m/e):398(M+),291,212,186(BP),146,104,77 [0186]
    [0187] IR(cm[0187] −1):3022,2914,1608,1509,1452,1242,738,714
    [0188] [0188] 1HNMR(CDCl3) δ: 2.37 (S, 3H, —CH3), 2.98 (t, 2H, —CH2—, J=6.83, 6.84 Hz), 3.73 (S, 2H, —CH2—), 3.78 (S, 2H, —CH2—), 4.24 (t, 2H, —CH2—, J=6.84, 6.83 Hz), 6.86 (d, 2H, aromatic, J=8.79 Hz), 7.21-7.44 (m, 10H, aromatic), 7.97 (q, 2H, aromatic, J=1.46, 1.95 Hz)
    [0189] (b) 5-Methyl-4-(2-p-aminophenoxy)ethyl-2-phenyl-1,3-oxazole [0189]
    [0190] The compound (0.4 g) obtained from the above mentioned Example 9 step (a) was dissolved in methanol (10 mL) containing a small amount of HOAc and 5% Pd—C (80 mg). The mixture is hydrogenated and the reaction mixture was filtered and the filtrate was evaporated. A resulting residue was purified by silicagel column chromatography using a eluant (CHCl[0190] 3:MeOH=10:1). The objective compound (0.21 g, 67.7%) was obtained. m.p.=149-152° C.
    [0191] MASS(m/e):308(M+),291,186(BP),144,122,104,77 [0191]
    [0192] IR(cm[0192] −1):3430,2962,1608,1248
    [0193] [0193] 1HNMR(CDCl3) δ: 3.88 (S, 2H, —CH2—), 4.23 (t, 2H, —CH2—, J=6.34, 6.84 Hz), 6.90 (d, 2H, aromatic, J=8.79 Hz), 7.27 (d, 2H, aromatic, J=8.78 Hz), 7.41-7.46 (m, 3H, aromatic), 7.96 (d, 2H, aromatic, J=7.81 Hz)
    [0194] (c) 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy)benzyl]trifluoromethyl sulfonamide (compound 9) [0194]
    [0195] The compound (0.14 g) obtained from the above mentioned Example 9 step (b) was reacted with trifluoromethanesulfonamide as same manner as Example 2 and the objective compound (compound 9) was obtained (0.55 g, 28%). m.p.=113-115° C. [0195]
    [0196] MASS(m/e):440(M+),186,144,104(BP),77 [0196]
    [0197] IR(cm[0197] −1):3310,1443,1368,1251,1227,1188,1146
    [0198] [0198] 1HNMR(CDCl3) δ: 2.38 (S, 3H, —CH3), 2.98 (t, 2H, —CH2—, J=6.83, 6.84 Hz), 4.25 (t, 2H, —CH2—, J=6.84, 6.34 Hz), 4.37 (d, 2H, —CH2—, J=4.89 Hz), 5.05 (bs, 1H, —NHSO2—), 6.90 (d, 2H, aromatic, J=8.79 Hz), 7.22 (d, 2H, aromatic, J=8.79 Hz), 7.41-7.45 (m, 3H, aromatic), 7.97 (q, 2H, aromatic, J=1.95, 1.96 Hz) Example 10
    [0199] 4-[2-(5-Ethylpyridine-2-yl)ethoxy]benzene trifluoromethylsulfonamide (compound 10) [0199]
    [0200] (a) 2-[2-(4-Nitrophenoxy)]ethyl-5-ethyl-pyridine [0200]
    [0201] To a mixture of 2-(5-ethylpyridine) ethanol (10 g) and 4-fluoronitrobenzene (9.3 g) in Dimethylformamide (100 mL) was added NaOH (3.4 g) and the mixture was stirred at 0° C. for 1 hour. After pouring into ice-water, the product was extracted with ethyl acetate (150 mL). The ethyl acetate phase was washed with satd. NaCl and dried over anhydrous Na[0201] 2SO4. After removing the solvent, the resulting residue was purified by silicagel column chromatography (EtoAc:n-hexane=1:2→2:1). Recrystallization from EtoAc n-hexane mixture (1:1) gave the off-white objective compound. 13.4 g (74.4%), m.p.=45-47° C.
    [0202] MASS(m/e):272(M+), 150,134(BP), 119,93,77 [0202]
    [0203] IR(cm[0203] −1):1593,1518,1491,1341,1260,1008,834
    [0204] [0204] 1HNMR(CDCl3) δ: 1.25 (t, 3H, —C2H5, J=7.81, 7.32 Hz), 2.64 (q, 2H, —C2H5, J=7.33, 7.32 Hz), 3.27 (t, 2H, —CH2—, J=6.34, 6.84 Hz), 4.46 (t, 2H, —CH2—, J=6.34, 6.84 Hz), 7.17 (d, 1H, pyridine, J=8.31 Hz), 7.47 (dd, 1H, pyridine, J=2.44, 2.45 Hz), 8.18 (dd, 2H, aromatic, J=6.83, 7.32 Hz), 8.40 (d, 1H, pyridine, J=1.95 Hz)
    [0205] (b) 2-[2-(4-Aminophenoxy)]ethyl-5-ethyl-pyridine [0205]
    [0206] The compound (1.85 g) obtained from the above mentioned Example 10 step (a) was hydrogenated as same manner as Example 1 step (c) and obtained the oily objective compound (1.62 g, 98.2%). [0206]
    [0207] MASS(m/e):242(M+), 134(BP), 119,106,83,65 [0207]
    [0208] IR(cm[0208] −1):2950,1509,1233,822
    [0209] [0209] 1HNMR(CDCl3) δ: 1.24 (t, 3H, —C2H5, J=7.81, 7.33 Hz), 2.62 (q, 2H, —C2H5, J=7.33 Hz), 3.19 (t, 2H, —CH2—, J=6.35, 6.83 Hz), 3.42 (bs, 2H, —NH2), 4.26 (t, 2H, —CH2—, J=6.35, 6.84 Hz), 6.61-6.64 (m, 2H, aromatic), 6.72-6.76 (m, 2H, aromatic), 7.18 (d, 1H, pyridine, J=7.81 Hz), 7.44 (dd, 1H, pyridine, J=1.95, 1.96 Hz), 8.39 (d, 1H, pyridine, J=2.46 Hz)
    [0210] (c) 4-[2-(5-Ethylpyridine-2-yl)ethoxy]benzene trifluoromethylsulfonamide (compound 10) [0210]
    [0211] The compound (1.2 g) obtained from the above mentioned Example 10 step (b) was reacted with trifluoromethanesulfonic acid anhydride by the same procedure described in Example 2 and obtained 0.3 g the objective compound (compound 10). m.p.=76-78° C. [0211]
    [0212] MASS(m/e):373(M+−1),134(BP),91,69 [0212]
    [0213] IR(cm[0213] −1):1446,1263,1119,897,603
    [0214] [0214] 1HNMR(CDCl3) δ: 1.25(t, 3H, —C2H5, J=7.81, 7.33 Hz), 2.63 (q, 2H, —C2H5, J=7.32, 7.82 Hz), 3.25 (t, 2H, —CH2—, J=6.83, 6.35 Hz), 4.39 (t, 2H, —CH2—, J=6.35 Hz), 6.96 (dd, 2H, aromatic, J=6.84, 6.83 Hz), 7.18 (d, 1H, pyridine, J=7.81 Hz), 7.28 (d, 2H, aromatic, J=9.28 Hz), 7.46 (dd, 1H, pyridine, J=7.81 Hz), 8.40 (d, 1H, pyridine, J=1.96 Hz) Example 11
    [0215] 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]benzene trifluoromethanesulonamide (compound 11) [0215]
    [0216] (a) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-1-nitrobenzene-2-pyridyl-2-methylamino ethanol (4.0 g) was reacted with 4-fluorobenzene by the same procedure described in Example 6 step (a) and obtained the oily objective compound (5.9 g, 82.2%). [0216]
    [0217] MASS(m/e):273(M+),139,121(BP),94,78,51 [0217]
    [0218] IR(cm[0218] −1):2926,1590,1497,1425,1338,1260
    [0219] [0219] 1HNMR(CDCl3) δ: 3.14 (S, 3H, —CH3), 4.03 (t, 2H, —CH2, J=5.86, 5.37 Hz), 4.30 (t, 2H, —CH2—, J=5.86 Hz), 5.52 (d, 1H, pyridine, J=8.79 Hz), 6.59 (t, 1H, pyridine, J=4.88, 6.35 Hz), 6.97 (dd, 2H, aromatic, J=8.79 Hz), 7.45-7.50 (m, 1H, pyridine), 8.15-8.20 (m, 2H, pyridine, aromatic)
    [0220] (b) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-1-aminobenzene [0220]
    [0221] The compound (5.85 g) obtained from the above mentioned Example 11 step (a) was hydrogenated by the same procedure described in Example 1 step (c) and obtained the objective compound (2.12 g, 40.7%). [0221]
    [0222] MASS(m/e):243(M+), 135(BP),121,108,94,78,65 [0222]
    [0223] IR(cm[0223] −1):3334,2914,1596,1557,1503,1425,1233,771
    [0224] (c) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]benzene trifluoromethanesulfonamide (compound 11) [0224]
    [0225] The compound (0.5 g) obtained from the above mentioned Example 11 step (b) was reacted with trifluoromethanesulfonamide by the same procedure described in Example 2 and obtained the objective product (0.67 g, 87.0%). m.p.=60-62° C. [0225]
    [0226] MASS(m/e):375(M+),304,170,135,108,78(BP),52 [0226]
    [0227] IR(cm[0227] −1):1593,1503,1452,1218,1125,891,600
    [0228] [0228] 1HNMR(CDCl3) δ: 3.13 (S, 3H, —CH3), 4.01 (t, 2H, —CH2, J=5.86, 5.37 Hz), 4.24 (t, 2H, —CH2—, J=5.86, 5.37 Hz), 6.51 (d, 1H, pyridine, J=8.30 Hz), 6.57 (t, 1H, pyridine, J=4.88, 6.84 Hz), 6.97 (d, 2H, aromatic, J=9.27 Hz), 7.27 (d, 2H, aromatic, J=9.77 Hz), 7.44-7.49 (m, 1H, pyridine), 8.15 (d, 1H, pyridine, J=3.90 Hz) Example 12-17
    [0229] According to the method described in Example 1, compound 12 (m.p.=106-108° C.), compound 13(m.p.=67-68° C.), compound 14 (m.p.=56-58° C.), compound 15 (m.p.=128-130° C.), compound 16 (126-127° C.) and compound 17 (m.p.=128-130° C.) were obtained. [0229] Example 18-20
    [0230] According to the method described in Example 2, compound 18 (m.p.=197-198° C.), compound 19 (m.p.=70-71° C.) and compound 20 (m.p.=170-172° C.) were obtained. [0230] Example 21
    [0231] 5-Methyl-4-(3-hydroxy)propyl-2-phenyl-1,3-oxazole, prepared from glutamic acid instead of asparatic acid, was reacted as a similar manner described in Experimental 2 and obtained compound 21 (m.p.=113-114° C.). [0231] Example 22-24
    [0232] According to the same procedure described in Example 4, compound 22 (m.p.=128-130° C.) and compound 23 (m.p.=217° C. (decomp.)) were obtained. [0232] Example 25
    [0233] 2—Hydroxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid methyl ester (compound 25) [0233]
    [0234] 0.2 g of methyl 2-4-dihydroxybenzoate and 0.23 g of diisopropyl azodicarboxylate (DIAD) were dissolved in 2 mL of THF. To this mixture was slowly added a mixture of 0.29 g of 5-methyl-4-hydroxyethyl-3-phenyl-1,3-oxazole and 0.31 g of Ph[0234] 3P in 3 mL of THF and the mixture was subjected to Mitsunobu reaction. After the reaction mixture was allowed to stand over night, the solvent was removed. The resulting residue was purified by silicagel column chromatography (ethyl acetate:benzene=1:5). After removing the solvent, the residue was recrystallized from benzene. 0.31 g (73.3%) of the colorless objective compound was obtained. m.p.=133-134° C.
    [0235] MASS(m/e):353(M+),217,185,136,104(BP),77,53 [0235]
    [0236] IR(cm[0236] −1):1677,1617,1440,1320,1251,1188,1134
    [0237] [0237] 1HNMR(CDCl3) δ: 3.90 (S, 3H, —COOMe), 4.27 (t, 2H, —CH2, J=6.34, 6.84 Hz), 6.42 (dd, 1H, −aromatic, J=8.79 Hz), 6.46 (d, 1H, aromatic, J=2.44 Hz), 7.39-7.44 (m, 3H, aromatic), 7.72 (d, 1H, aromatic, J=9.28 Hz), 7.97 (q, 2H, aromatic, J=7.33, 8.3 Hz), 10.93 (s, 1H, —OH) Example 26-28
    [0238] According to the procedure described in Example 11, compound 26 (m.p.=211-213° C.), compound27 (m.p.=85-87° C.) and compound 28 (m.p.=130-132° C.) were obtained. [0238] Example 29-30
    [0239] 2—Hydroxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid (compound 29) [0239]
    [0240] 0.17 g of the compound obtained from Example 20 was dissolved in 2 mL of MeOH:THF (1:1). To the solution was added 2 mL of 10% NaOH and the mixture was refluxed for 1 hour. After removal of the solvent, the residue was washed with ether, followed by acidification with 10% HCl. The resulting precipitate was filtered. Recrystallization from ethanol gave the colorless objective compound (0.13 g, 81.3%). m.p.=192-194° C. [0240]
    [0241] MASS(m/e):339(M+),295,217,186,104(BP) [0241]
    [0242] IR(cm[0242] −1):2920,1655,1260,1170
    [0243] According to the above mentioned procedure compound 30 was obtained. (m.p.=246-266° C.). [0243] Example 31-32
    [0244] 2-Ethoxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid (compound 31) [0244]
    [0245] (a) 2-Ethoxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid methyl ester [0245]
    [0246] To a solution of the compound 25 (0.27 g) in DMF (5 mL) was added K[0246] 2CO3 (0.16 g) and EtI (0.07 mL) and the mixture was allowed to stand over night. The reaction mixture was poured into water and the product was extracted with ethyl acetate (30 mL). The ethyl acetate phase was washed with water, satd. NaCl and dried over anhydrous Na2SO4 and filtrated. Evaporation of the filtered gave a residue, from which 0.28 g (96.6%) of the colorless objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane =1:3).
    [0247] MASS(m/e):381(M+),217,186,144,104(BP),77,51 [0247]
    [0248] IR(cm[0248] −1):2926,1686,1605,1257,1194
    [0249] (b) 2-Ethoxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy]benzoic acid (compound 31) [0249]
    [0250] The compound obtained from above mentioned Example 31-32 step (a) was hydrolyzed by the procedure in Example 29 and obtained the objective compound (0.22 g). m.p.=128-130° C. [0250]
    [0251] MASS(m/e):367(M+),217,186,144,104(BP),77,51 [0251]
    [0252] IR(cm[0252] −1):1686,1605,1572,1281,1263,1239,1191
    [0253] [0253] 1HNMR(CDCl3) δ: 2.99 (t, 2H, —CH2—, J=6.84 Hz), 4.25 (q, 2H, oEt, J=6.84 Hz), 4.33 (t, 2H, —CH2—, J=6.34, 6.84 Hz), 6.50 (d, 1H, aromatic, J=2.44 Hz), 6.55 (dd, 1H, aromatic, J=1.95 Hz), 7.41-7.44 (m, 3H, aromatic), 7.96-7.99 (m, 2H, aromatic), 8.10 (d, 1H, aromatic, J=8.79 Hz)
    [0254] And compound 25 was reacted with methoxy methylchloride to obtain compound 32. m.p.=129-130° C. [0254] Example 33-38
    [0255] Each compounds of 3-benzyl-4-nitrophenol-2,6-difluoro-4-nitrophenol and 5-methyl-4-hydroxyethyl-2-phenyl-1,3-oxazole were subjected to Mitsunobu reaction in a similar manner described in Example 25 and the nitro compounds were obtained, followed by the procedures described in Example 1 step (c) and step (d) yielded compound 33 (m.p.=155-156° C.), compound35 (m.p.=143-144° C.) and compound 36 (m.p.=78-80° C.). Further, Mitsunobu reaction of 2,4-dihydroxy-benzene sulfonamide and 5-methyl-4-hydroxy-3-phenyl-1,3-oxazole yielded compound 34 (m.p.=231-232° C.). Ethylation of the compound 34 yielded compound 37 (m.p.=171-173° C.). Methyl 4-hydroxy-2-ethoxyphenoxy acetate was reacted in a similar manner and the resulting compound was hydrolyzed to obtain compound 38 (m.p.=154-156° C.). [0255] Example 39
    [0256] 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-2-hydroxyphenyl trifluoromethane sulfonamide (compound 39) [0256]
    [0257] (a) 4-[2-(N-Methyl-2—N-pyridyl)aminoethoxy]-2-hydroxy nitrobenzene. [0257]
    [0258] To a mixture of 2-(N-methyl, N-hydroxyethyl)-aminopyridine (0.35 g) and 4-fluoro-2-methoxy-methyloxy-nitrobenzene in DMF (30 mL) was added NaH (0.12 g) and stirred at room temperature over night. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The ethyl acetate extract was washed with satd. NHCl and dried over anhyd. Na[0258] 2SO4 and filtered. After removal of solvent, the residue was purified by silicagel column chromatography (ethyl acetate:n-hexane=1:2). The oily objective compound (0.44 g, 57.1 %) was obtained.
    [0259] MASS(m/e):333(M+),121(BP),78,52 [0259]
    [0260] IR(cm[0260] −1):2926,1596,1500,1425,1341,1287,1152
    [0261] (b) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-2-hydroxyphenyl trifluoromethanesulfonamide (compound 33) [0261]
    [0262] The compound obtained from the above mentioned step (a) was reduced with hydrogen in a similar manner described in Example 1 step (c) and the resulting compound was reacted with trifluoromethanesulfonic acid anhydride in a similar manner described in Experimental 1 step (d). After removing of the protection group (MOM, methoxymethyl), the residue was recrystallized from the mixture of ethyl acetate and n-hexane to obtain the colorless objective compound (compound 33). mp-134-135° C. [0262]
    [0263] MASS(m/e):391 (M+),135(BP),107,78 [0263]
    [0264] IR(cm−1):1611,1509,1419,1404,1227,1176,1146 [0264]
    [0265] [0265] 1HNMR(CDCl3) δ: 3.14 (S, 3H, Me), 3.93 (t, 2H, —CH2, J=5.37 Hz), 4.11 (2H, —CH2—, J=5.37 Hz), 6.37-6.43, 6.53-6.59 (m, m, 4H, aromatic, pyridine), 7.27 (d, 1H, aromatic, J=8.79 Hz), 7.46-7.51 (m, 1H, pyridine), 8.08 (d, 1H, pyridine, J=4.88 Hz) Example 40-41
    [0266] Compound 40 (m.p.=133-135° C.) and compound 41(m.p.=151-153° C.) were obtain from 4-fluoro-2-ethoxy-nitrobenzene by proceeding in a similar manner described in Experimental 39 step (a). [0266] Example 42-45
    [0267] In stead of 2-(N-Methyl, N-hydroxyethyl) aminopyridine in Example 39 step (a), 5-methyl-4-hydroxy-2-phenyl-1,3-oxazole was reacted in a similar manner and the resulting compound was reacted with trifluoromethanesulfonic acid anhydride to obtain compound 43 (m.p.=169-171° C.). The compound obtained from Example 39 step (a) was reacted with trifluoromethanesulfonic acid anhydride to obtain compound 44 (m.p.=124-125° C.). Further, 2-(N-Methyl, N-hydroxyethyl)-amino pyridine in Example 39 step (a) was reacted with 4-fluoro-2-methoxy-nitrobenzene and the resulting product was treated with in a similar manner described in Example 1 step (c) to obtain the oily objective compound 45. [0267] Example 46-47
    [0268] N-Butyl-2,4-dihydroxy-benzenesulfonamide and 5-methyl-4-bromoethyl-2-phenyl-1,3-oxazole was reacted in a similar manner described in Example 1 step (b) to obtain compound 46 (m.p.=137-139° C.). After reacting 2,6-dibromo-4-hydroxy-benzoic acid methyl ester and 5-methyl-4-bromoetyl-2-phenyl-1,3-oxazole, compound 47 (m.p.=163-164° C.) was obtained. [0268] Example 48-54
    [0269] After chlorination of the compound of general formula (68), the resulting compound was reacted with 4-nitroaniline or corresponding aniline to obtain the compound of general formula (69), followed by reduction in a similar manner described in Example 1 and the resulting compounds were treated in a similar manner described in Example 2. The following objective compounds were obtained. Compound 53 was hydrolyzed to obtain compound 54. Compound 48 (m.p.=147-149° C.), compound 49 (m.p.=175-177° C.), compound 50 (m.p=166-168° C.), compound 51 (m.p.=164-166° C.), compound 52 (m.p.=227-229° C.), compound 53 (oil), compound 54 (175° C., decomp.) [0269] Example 55-56
    [0270] After activation of carboxylic acid group in general formula (71) by the reported method (Bioorg.Med.Chem.Lett., 1995,1155), the resulting compound was reacted with sulfamines in the presence of DBU to obtain compound 55 (m.p.=150-152° C.) and compound 56 (m.p.=214-216° C.). [0270] Example 57-59
    [0271] In stead of 5-methyl-4-p-aminophenoxy-2-phenyl-1,3-oxazole in Example 2, 5-methyl-4-p-aminophenoxyethyl-2-p-tolyl-1,3-oxazole, 5-methyl-4-p-aminophenoxyethyl-2-p-chlorophenyl-1,3-oxazole and 5-methyl-4-p-aminophenoxyethyl-2-p-fluorophenyl-1,3-oxazole were reacted in a similar manner described in Example 2 to obtain the following compounds. Compound 57 (m.p.=173.5-175° C.), compound 58 (m.p.=189-190° C.), compound 59 (m.p.=161-163° C.). [0271] Example 60-63
    [0272] In stead of 5-methyl-4-p-aminophenoxy-2-phenyl-1,3-oxazole, 5-isopropyl-4-p-aminophenoxy-ethyl-2-p-tolyl-1,3-oxazole, 5-isopropyl-4-p-aminophenoxy-2-phenyl-1,3-oxazole, 5-isopropyl-4-p-aminophenoxyethyl-2-p-fluorophenyl-1,3-oxazole and 5-isopropyl-4-p-aminophenoxy-2-(3,5-di-t-butyl-4-hydroxy)phenyl-1,3-oxazole were reacted in a similar manner described in Example 2 to obtain the following compounds. Compound 60 (m.p.=190-191° C.), compound 61 (m.p.=155-156° C.), compound 62 (m.p.=189-190° C.), compound 63 (m.p.=142-144° C.). Example 64-66 [0272]
    [0273] 5-Isopropyl-4-hydroxyethyl-2-phenyl-1,3-oxazole, 5-isopropyl-4-hydroxyethyl-2-p-phenyl-1,3-oxazole and 5-isopropyl-4-hydroxyethyl-2-p-tolyl-1,3-oxazole were reacted with 4-fluoro-2-ethoxy-nitrobenzene in a similar manner described in Example 39 to obtain the following compounds. Compound 64 (m.p.=142-144° C.), compound 65 (m.p.=179-181° C.), Compound 66 (m.p.=122-124° C.) [0273] Example 67-68
    [0274] Each of 5-methyl-4-hydroxyethyl-2-(p-ethoxycarbonylmethyloxy)phenyl-1,3-oxazole and 5-methyl-4-hydroxyethyl-2-(3,5-di-t-butyl-4-ethoxycarbonylmethyloxy)phenyl-1,3 -oxazole were transformed to 5-methyl-4-p-nitrophenyl -2-(p-ethoxycarbonylmethyloxy)phenyl-1,3-oxazole and 5-methyl-4-p-nitrophenyl-2-(3,5-di-t-butyl-4-ethoxycarbomethyloxy)phenyl-1,3-oxazole using a similar method described in Example 39. The resulting compounds were hydrolyzed with 10% NaOH—MeOH to obtain the following compounds. Compound 67 (m.p.=167-168° C.), compound 68 (m.p.=196-198° C.) [0274] Example 69
    [0275] 5-Methyl-4-p-formylphenyl-2-phenyl-1,3-oxazole (1.0 g) was dissolved in dichlolomethane (10 mL) and hydroxylamine-o-sulfonic acid (0.59 g) was added. The mixture was stirred for 30 minutes and the resulting precipitate was collected, followed by washing with water, MeOH and dichloromethane. 1.03 g of compound 69 was obtained. m.p.=165-167° C. [0275]
    [0276] MASS(m/e):403(M+1),401(M−1) [0276] Example70
    [0277] According to a similar procedure, described in Example 2, 5-methyl-4-aminophenoxyethyl-2-(3-t-butyl-4-hydroxy)phenyl-1,3-oxazole were transformed to compound 70. m.p.=58-60° C. [0277]
    [0278] Effects of the Invention [0278]
    [0279] This invention concerns to novel ether and/or amide derivatives which enhance insulin action and show hypoglycemic activities with low toxicities and useful for antidiabetics. [0279]
    权利要求:
    Claims (19)
    [1" id="US-20010008898-A1-CLM-00001] 1. A compound of the general formula (I),
    R1—A—R2  (I)
    [2" id="US-20010008898-A1-CLM-00002] 2. A compound of
    claim 1 wherein
    [3" id="US-20010008898-A1-CLM-00003] 3. A compound of
    claim 1 wherein
    [4" id="US-20010008898-A1-CLM-00004] 4. A compound of
    claim 1 wherein
    [5" id="US-20010008898-A1-CLM-00005] 5. A compound of
    claim 1 wherein
    [6" id="US-20010008898-A1-CLM-00006] 6. A pharmaceutical composition according to
    claim 1 for use as antidiabetics.
    [7" id="US-20010008898-A1-CLM-00007] 7. A process for the production of a compound of general formula (I) wherein A is —O—;
    [8" id="US-20010008898-A1-CLM-00008] 8. A process for the production of a compound of the general formula (I) wherein A is —O—;
    [9" id="US-20010008898-A1-CLM-00009] 9. A process for the production of a compound of the general formula (I) wherein A is —O—; R has the above-mentioned meanings;
    [10" id="US-20010008898-A1-CLM-00010] 10. A process for the production of a compound of the general formula (I) wherein A is —O—; R2 has the above-mentioned meanings;
    [11" id="US-20010008898-A1-CLM-00011] 11. A process for the production of a compound of general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [12" id="US-20010008898-A1-CLM-00012] 12. A process for the production of a compound of the general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [13" id="US-20010008898-A1-CLM-00013] 13. A process for the production of a compound of the general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [14" id="US-20010008898-A1-CLM-00014] 14. A process for the production of a compound of the general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [15" id="US-20010008898-A1-CLM-00015] 15. A method of manufacturing a compound of the general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [16" id="US-20010008898-A1-CLM-00016] 16. A method for manufacturing a compound of the genaral formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [17" id="US-20010008898-A1-CLM-00017] 17. A method for manufacturing a compound of the general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [18" id="US-20010008898-A1-CLM-00018] 18. A method for manufacturing a compound of the general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    [19" id="US-20010008898-A1-CLM-00019] 19. A method for manufacturing a compound of the general formula (I) wherein A is —O—;
    R2 has the above-mentioned meanings;
    which comprises a reaction of a compound of general formula;
    (in which R2 has the above-mentioned meanings) with H2NOSO3H to obtain the compound of general formula (I).
    类似技术:
    公开号 | 公开日 | 专利标题
    US6414001B2|2002-07-02|Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics
    US20070149589A1|2007-06-28|Process for the Preparation of 4-|benzamidines
    ES2279310T3|2007-08-16|DERIVATIVES OF HETEROCICLIC OXIMES, ITS PREPARATION PROCEDURE AND ITS USE IN THE TREATMENT OF TYPE II DIABETES.
    SK282080B6|2001-10-08|Substituted salicylic acids
    JP4571075B2|2010-10-27|Amide type carboxamide derivatives
    US5710152A|1998-01-20|Benzoazine derivative or salt thereof and pharmaceutical compostion comprising the same
    JP2000515133A|2000-11-14|Hypoglycemic and hypolipidemic compounds
    JP2767321B2|1998-06-18|Piperazine derivative and drug containing the same
    EP0398179B1|1996-01-17|Rhodanine derivatives and pharmaceutical compositions
    JP2006298909A|2006-11-02|Medicine composition
    JPH0649047A|1994-02-22|New phenylcarboxamidoisoxazole derivative and its salt, their production, new intermediate for producing them, their use as drug, and drug composition containing them
    US6727266B2|2004-04-27|Substituted tryptophan derivatives
    DK159435B|1990-10-15|METHOD OF ANALOGUE FOR PREPARING 2-HYDROXY-5- | BENZOIC ACID DERIVATIVES OR A PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT
    US5013734A|1991-05-07|Novel esters of phenylalkanoic acid
    EP0735029B1|1998-06-03|Benzothiazole derivatives
    US5063246A|1991-11-05|Phenethylamine derivative compositions and use
    HU202506B|1991-03-28|Process for producing benzoxazolone derivatives
    FR2593178A1|1987-07-24|2-BENZIMIDAZOLYLALKYLTHIO | DERIVATIVES THEIR PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS.
    JP3466273B2|2003-11-10|Tetrazole derivative, method for producing the same, and medicament comprising the same
    JP3529112B2|2004-05-24|2- [2- | benzylthio] -5,6,7,8-tetrahydropyrido [4,3-d] pyrimidin-4 | -one derivative
    US5041462A|1991-08-20|Novel substituted acetamide compounds and use as anti-allergic agents
    US6919328B1|2005-07-19|Tricyclic compounds with NOS activity
    US6339083B1|2002-01-15|Multiheterocyclic pharmAceuticals
    JP2000355537A|2000-12-26|Sodium ion/calcium ion exchange system inhibitor
    JPH0912563A|1997-01-14|New benzylalcohol derivative, its production and its use
    同族专利:
    公开号 | 公开日
    GB0100433D0|2001-02-21|
    ES2187261B2|2004-07-16|
    JP2001261662A|2001-09-26|
    ES2187261A1|2003-05-16|
    FR2804681B1|2004-06-25|
    KR20010070442A|2001-07-25|
    CN1227231C|2005-11-16|
    FR2804681A1|2001-08-10|
    JP4316787B2|2009-08-19|
    DE10100772A1|2001-07-19|
    US6414001B2|2002-07-02|
    GB2359082B|2004-09-29|
    ITMI20010042A1|2002-07-11|
    CN1315320A|2001-10-03|
    GB2359082A|2001-08-15|
    DE10100772B4|2005-09-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2002088120A1|2001-04-26|2002-11-07|Léciva, a.s.|Method for obtaining pioglitazone as an antidiabetic agent|
    US20030171377A1|2001-08-29|2003-09-11|Bigge Christopher Franklin|Antidiabetic agents|
    US6716842B2|2002-04-05|2004-04-06|Warner-Lambert Company, Llc|Antidiabetic agents|
    US20040176395A1|2002-12-31|2004-09-09|Flynn Daniel L|Anti-cancer medicaments|
    US20050267665A1|2004-05-12|2005-12-01|Toyota Jidosha Kabushiki Kaisha|Deceleration control system and deceleration control method for vehicle|
    US20050288286A1|2003-12-24|2005-12-29|Flynn Daniel L|Anti-inflammatory medicaments|
    WO2006018116A1|2004-08-14|2006-02-23|Sanofi-Aventis Deutschland Gmbh|N--cyclohexyl-succinic acid amide derivatives and related compounds which are used as ppar-ligandsfor the treatment of hyperlipidaemie and diabetes|
    US7144911B2|2002-12-31|2006-12-05|Deciphera Pharmaceuticals Llc|Anti-inflammatory medicaments|
    US20080045531A1|2002-12-31|2008-02-21|Flynn Daniel L|Anti-inflammatory medicaments|
    KR100913471B1|2001-10-25|2009-08-25|일라이 릴리 앤드 캄파니|Thiopene- and Thiazolesulfonamides as Antineoplastic Agents|HU217432B|1988-03-08|2000-01-28|Pfizer Inc.|Process for producing thiazolidine-dion derivatives and pharmaceutical compositions containing the same the compounds and compositions|
    US5239080A|1989-02-08|1993-08-24|Takeda Chemical Industries, Ltd.|Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents|
    ES2067945T3|1990-08-23|1995-04-01|Pfizer|DERIVATIVES OF HYPOGLYCEMIC HYDROXYUREA.|
    TW245716B|1992-12-28|1995-04-21|Takeda Pharm Industry Co||
    TW268952B|1993-02-26|1996-01-21|Takeda Pharm Industry Co Ltd||
    US5641796A|1994-11-01|1997-06-24|Eli Lilly And Company|Oral hypoglycemic agents|
    GB9604242D0|1996-02-28|1996-05-01|Glaxo Wellcome Inc|Chemical compounds|
    CZ53699A3|1996-08-19|1999-07-14|Japan Tobacco Inc.|Derivatives of propionic acid and their use|
    WO1999046232A1|1998-03-10|1999-09-16|Ono Pharmaceutical Co., Ltd.|Carboxylic acid derivatives and drugs containing the same as the active ingredient|
    WO2001016111A2|1999-08-27|2001-03-08|Eli Lilly And Company|Hypoglycemic sulfonyl pyrazolones and pyrazolines|
    US6617343B1|1999-08-27|2003-09-09|Eli Lilly And Company|Hypoglycemic N,N-arylsulfonylglycine compounds|MXPA03001558A|2000-08-23|2003-06-06|Lilly Co Eli|Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists.|
    US7176224B2|2000-08-23|2007-02-13|Eli Lilly And Company|Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists|
    DE60129712T2|2000-08-23|2008-07-03|Eli Lilly And Co., Indianapolis|OXAZOLYLARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS|
    KR20040030658A|2001-06-07|2004-04-09|일라이 릴리 앤드 캄파니|Modulators of peroxisome proliferator activated receptors|
    AT382043T|2003-02-14|2008-01-15|Lilly Co Eli|SULFONAMIDE DERIVATIVES AS PPAR MODULATORS|
    US7348453B2|2003-09-04|2008-03-25|Mirus Bio Corporation|Labile linkage for compound delivery to a cell|
    PT1650186E|2004-10-22|2008-09-16|Bioprojet Soc Civ|Novel dicarboxylic acid derivatives|
    CN101735048A|2008-11-05|2010-06-16|上海慈瑞医药科技有限公司|Salicylic acid compounds with insulin-sensitizing activity and preparation method thereof|
    US8933236B2|2012-05-22|2015-01-13|Xenon Pharmaceuticals Inc.|N-substituted benzamides and methods of use thereof|
    BR112015000187A2|2012-07-06|2017-06-27|Genentech Inc|benzamides substituted with n and methods of use thereof|
    BR112015008987A2|2012-10-26|2017-07-04|Merck Sharp & Dohme|compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a pharmaceutical composition|
    法律状态:
    2001-02-26| AS| Assignment|Owner name: KOTOBUKI PHARMACEUTICAL CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TOMIYAMA, TSUYOSHI;TOMIYAMA, AKIRA;TOMIYAMA, HIROSHI;AND OTHERS;REEL/FRAME:011540/0272 Effective date: 20010122 |
    2006-01-03| FPAY| Fee payment|Year of fee payment: 4 |
    2010-02-08| REMI| Maintenance fee reminder mailed|
    2010-07-02| LAPS| Lapse for failure to pay maintenance fees|
    2010-08-02| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2010-08-24| FP| Expired due to failure to pay maintenance fee|Effective date: 20100702 |
    优先权:
    申请号 | 申请日 | 专利标题
    JP2000-006106||2000-01-11||
    JP6106/2000||2000-01-11||
    JP2000006106||2000-01-11||
    JP2000-356303||2000-11-22||
    JP2000356303A|JP4316787B2|2000-01-11|2000-11-22|An ether or amide derivative, a process for producing the same, and a therapeutic agent for diabetes containing the same,|
    [返回顶部]